Navigation Links
Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.

LOS ANGELES, Oct. 9 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP). "Raptor's management team was pivotal in getting two drugs approved and creating stockholder value while at BioMarin Pharmaceutical, a $2.4B biotech company and we believe they will do it again with Raptor," stated Ross Silver, Director of Research at Vista Partners. Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. For more information and to download the report; please visit the Vista Partners website at

About Raptor:

Raptor Pharmaceuticals Corp.'s (the "Company") sole business is its 100% ownership of Raptor Pharmaceutical Inc., a development stage biotechnology company which bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins. The Company's preclinical programs target cancer, neurodegenerative disorders, infectious diseases and osteoporosis. HepTide(TM) utilizes engineered RAP-based peptides conjugated to drugs to target their delivery to the liver. In neurodegenerative diseases, engineered RAP peptides called NeuroTrans(TM) are currently undergoing evaluation at Stanford University in cell culture and preclinical models for their ability to enhance the transport of molecules from blood to brain. In osteoporosis, Raptor is testing the ability of WntTide(TM), which are Mesd and engineered Mesd-based peptides and act through LRP5, a known determinant of bone density, to combat osteoporosis and increase bone density. In an effort to protect its novel approach, Raptor currently has five patent applications in review in the U.S., and countries in Europe and Asia, as well as two provisional patent applications licensed from Washington University. In addition, the Company has recently submitted two new provisional patent applications in the U.S., the first of which covers a new family of RAP peptides, with the second application to further support and expand the Company's coverage in specific disease indications.


Vista Partners LLC

Ross Silver

(415) 738-6229

SOURCE Vista Partners LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Evista Not A Cure For Heart Disease
2. Spouses and other partners lower blood pressure says new research
3. Changing Partners may put Expectant Mothers at Risk
4. British Healthcare Mission Explores Partnership Possibilities With Indian Healthcare Sector
5. Partnership Between Diabetes India And Elsevier Announced
6. Betterment Of Health In Case Of Gay And Lesbian Civil Partnerships
7. Private Public Partnership To Tackle TB, In Karnataka
8. Courting HIV through Marriage or Partnership
9. Jealousy In Men Peaks When Partners Are Most Fertile
10. War Trauma Not Passed On To Partners And Children, Study
11. SRM Inst Signs Mou With Partners Health Care
Post Your Comments:
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: